3rd International Conference on Polymyxins

3rd International Conference on Polymyxins is organized by University of Michigan Health System-Department of Internal Medicine and will be held during Apr 25 - 26, 2018 at Hospital October 12, Madrid, Spain.

The target audience for this medical event is academicians, clinicians, fellows, infectious diseases physicians, physicians-in-training, and pharmacists.

General Information :
Abstracts submitted to ECCMID 2018 or ASM Microbe 2018 will also be accepted for 3rd International Conference on Polymyxins. Please format abstracts using the same criteria as is required for abstracts submitted to ECCMID 2018. Formatting abstracts according to the ASM Microbe 2018 criteria is also acceptable.

Conference Description :
This opinion-leader conference will feature cutting-edge presentations by world leaders in research and clinical use of polymyxins, and regulatory and funding agency representatives. Each symposium session will provide opportunity for discussion and input from the audience.

Topics will include:
• Setting the Scence: Polymyxins in an Age of New Antibiotics
• Walking the Tightrope between Efficiancy and Toxicity
• Young Investigator Session: Oral Presentations for Polymyxin New and Upcoming Research
• Polymyxin Combinations:Thinking out of the Box and Clinical Use of Combinations
• The Road Ahead: Optimizing Clinical Use, Advances and Challenges

Conference Objectives are :
• Explain the Gram-negative antimicrobial resistance crisis and the role the polymyxins will play in an age of new antibiotics.
• Discuss the newest data regarding clinical studies of colistin and polymyxin B combinations.
• Define the mechanisms of action and resistance for the polymyxins.
• Summarize polymyxin use around the globe with an understanding of epidemiology and best practices.
• Summarize the optimized dosing and therapeutic drug monitoring of colistin and polymyxin B in patients and in special patient populations.
• Discuss new developments and best practices for MIC measurement and breakpoints.
• Explain the key differences between polymyxin B and colistin as it relates to nephrotoxicity and other toxicities when used in patients.
• Summarize important regulatory, agricultural and world health organization perspectives developments and actions around the globe.
• Define in vitro and in vivo pharmacokinetic and pharmacodynamic relationships of polymyxins and their combinations for optimal use.
• Summarize the key recommendations of the polymyxins guidelines.

Additional details will be posted as soon as they are available.